WIGRETTES

Post-LOE

ergotamine tartrate

Merck & Co.

ANDASUBLINGUALTABLET

Approved

Jul 1982

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

WIGRETTES (ergotamine tartrate) by Merck & Co. is clinical pharmacology ergotamine is an alpha adrenergic blocking agent with a direct stimulating effect on the smooth muscle of peripheral and cranial blood vessels and produces depression of central vasomotor centers. Approved for migraine. First approved in 1982.

Drug data last refreshed 1w ago

Mechanism of Action

CLINICAL PHARMACOLOGY Ergotamine is an alpha adrenergic blocking agent with a direct stimulating effect on the smooth muscle of peripheral and cranial blood vessels and produces depression of central vasomotor centers. The compound also has the properties of serotonin antagonism. In comparison to…

Indications (1)

migraine

Worked on WIGRETTES at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.